mr_p, thanks for your garnishing and sharing of facts. While inclusion of CTSO into the Russell micro-cap gives the company credibility as a viable corporate entity, it doesn't look like inclusion by itself will not do much for demand of the stock to to move the pps.
While the dollar amount is nominal, the fact that the doctor recognized using the filter as a viable therapy is extremely significant!
10. A potential Cardiac partner is evaluating the filter. Can you share what indication/application the filter is being evaluated for? Has the potential partner committed to time when their analysis will be complete? Can you share what may be unique about this particular partnership agreement?
Correct, they looked at the past two quarters and inferred that it is a trend. Not mentioned in the opinion was that the CTSO has increased production by adding a second shift.
The market Cap for CTSO is now about $180MM. It has not been that low for a long time. I picked up some more shares for my grand kids.
This is a study that can be done very rapidly and is the reason why we have nearly 300 -- actually more than 300 intraoperative cardiac surgery treatments already in Germany and in Austria.
How many of those 300 were neutral or negative?
With a Chronologically Orientation for Pessimism, Misunderstood and Buffoonery....
From the transcript Dr. Chan describes the REFRESH trial design for the cardiac bypass surgery - "....this reduction in free hemoglobin trial is a 20-patient multicenter feasibility study evaluating the safety of CytoSorb when used intraoperatively in a bypass circuit in a heart-lung machine during complex cardiac surgery. And the goal here again is to try to reduce levels of free hemoglobin and other inflammatory mediators that if left unabated can cause postoperative complications.The trial is on target to commence midyear and is expected to be completed before year end. It's very important to note that this is a much different trial than a critical care trial or an ICU trial. The only intervention is using CytoSorb in a bypass circuit during the three to five hours of the cardiac surgery. Its one and done. After the surgery all that is required of the study nurse and the clinical team just take blood -- blood draws every day and to evaluate the patient clinically, until the patient leaves the intensive care unit. This is a study that can be done very rapidly and is the reason why we have nearly 300 -- actually more than 300 intraoperative cardiac surgery treatments already in Germany and in Austria."
We could have some more data by year end.
From the transcript; Dr. Chan is giving a breakdown on status on the partnerships and talks of appling for Canadian approval, "We’ve also met the requirements to add Canadian registration to our ISO 13485 certification and this will allow CytoSorb to be registered in Canada once all Health Canada requirements have been met." That is the first I have heard that actionable steps have been taken for Canadian approval.
I agree - First thing this morning the quarterly financial report, I believe management is saying "let's just get the information out and put the issue behind us so that we are not preoccupied with it as we roll out for the future."
The purpose of the evaluation is minimize risk. If there is no cost to the arrangement why do an evaluation of the filters efficacy? I expect an up front payment or the mystery partner will assume the expense of a trial.
I wouldn't say a broken promise - CTSO is doing everything it said it would do. But the time frame estimated to accomplish the goals may be too aggressive as seems to always keeps getting pushed further out into the future.
"he is running 40 some odd trials" that is not the case. He is providing filter s for 40 investigational studies done by other Doc's, not trials.
The risk is post operative complications which would increase the expense of the recovery. You are right in that spending a grand or two will offset the cost when things go wrong. A hospital should be willing to absorb (but they'll just past the cost along with a huge markup) to ease demand for resources e.g. beds ,staff equipment, ect. The evidence in Germany and the upcoming FDA CBP trial will show the benefit of the filter. .